Lab
Firstox Laboratories, LLC
Firstox Laboratories, LLC was paid $1.34M by Medicaid between Oct 2018 and May 2023, across 70 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 44% of everything it billed.
33Billing provider infoFIRSTOX LABORATORIES, LLC
IRVING, TX 75063
IRVING, TX 75063
33aNPI1033650866assigned 03/13/2017
33bProvider typeClinical Medical Laboratory
28Total paid$1.34M
24GClaims96,437
24DCodes billed70
24AFirst – last monthOct 2018 – May 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#58 of 436
Median peer was paid$17K
This provider vs. median78×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 735 | $2K | |
| 2019 | 4,571 | $126K | |
| 2020 | 38,860 | $842K | |
| 2021 | 24,465 | $163K | |
| 2022 | 24,889 | $203K | |
| 2023 | 2,917 | $2K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 44% | 8,428 | 5,411 | $591K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 29% | 19,525 | 12,289 | $383K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 10% | 5,797 | 3,860 | $140K |
| 0054U | 8.1% | 2,184 | 1,246 | $109K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.0% | 1,984 | 1,390 | $27K |
| 80171 | 1.2% | 2,637 | 1,811 | $16K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 333 | 258 | $14K |
| 80346 | <1% | 1,695 | 1,046 | $5K | |
| 80362 | <1% | 2,029 | 1,252 | $4K | |
| 80361 | <1% | 1,775 | 1,093 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 292 | 229 | $4K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 731 | 419 | $2K |
58 more codes
| 80354 | <1% | 2,157 | $2K | |
| 80365 | <1% | 1,688 | $2K | |
| 80373 | <1% | 1,691 | $2K | |
| 80358 | <1% | 1,696 | $2K | |
| 80366 | <1% | 1,700 | $2K | |
| 80353 | <1% | 1,602 | $2K | |
| 80355 | <1% | 820 | $2K | |
| 80348 | <1% | 2,076 | $2K | |
| 80369 | <1% | 1,491 | $2K | |
| 80372 | <1% | 1,469 | $2K | |
| 80356 | <1% | 1,648 | $2K | |
| 80324 | <1% | 1,625 | $2K | |
| 80345 | <1% | 1,493 | $2K | |
| 80349 | <1% | 1,599 | $2K | |
| 80357 | <1% | 1,485 | $2K | |
| 80053 | Comprehensive metabolic panel | <1% | 2,164 | $1K |
| 80321 | <1% | 1,540 | $1K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,471 | $1K |
| 84252 | <1% | 745 | $738.65 | |
| 80061 | Lipid panel | <1% | 982 | $705.33 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 315 | $583.36 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,074 | $557.97 |
| 80360 | <1% | 585 | $460.30 | |
| 80164 | <1% | 373 | $422.55 | |
| 87653 | <1% | 685 | $354.39 | |
| 87500 | <1% | 526 | $352.92 | |
| 87481 | <1% | 639 | $327.83 | |
| 87640 | <1% | 689 | $270.36 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 646 | $257.86 |
| 83880 | <1% | 48 | $219.31 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 186 | $192.15 |
| 87641 | <1% | 514 | $187.80 | |
| 85027 | <1% | 287 | $132.21 | |
| 87581 | <1% | 19 | $85.50 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 19 | $85.50 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 21 | $85.50 |
| 83735 | <1% | 179 | $76.48 | |
| 81001 | <1% | 688 | $72.87 | |
| 80076 | <1% | 54 | $52.16 | |
| 84439 | <1% | 88 | $33.12 | |
| 87150 | <1% | 557 | $28.01 | |
| 82248 | <1% | 30 | $24.06 | |
| 84134 | <1% | 74 | $23.91 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 83 | $22.29 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 49 | $19.66 |
| 84153 | <1% | 20 | $16.06 | |
| 80177 | <1% | 15 | $10.57 | |
| 84481 | <1% | 31 | $7.40 | |
| 87186 | <1% | 20 | $7.27 | |
| 87563 | 0% | 51 | $0.00 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 26 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 4,679 | $0.00 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 375 | $0.00 |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 0% | 3,089 | $0.00 |
| 80363 | 0% | 89 | $0.00 | |
| 87088 | 0% | 23 | $0.00 | |
| 87507 | 0% | 19 | $0.00 | |
| 80350 | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWTON, PATRICK (CORPORATE CONTROLLER)
| Provider | Location | Paid |
|---|---|---|
| Synapse Analytical Labs LLC | Raleigh, NC | $2.16M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.